New York State Common Retirement Fund Decreases Holdings in IQVIA Holdings Inc. (NYSE:IQV)

New York State Common Retirement Fund lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 5.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 102,522 shares of the medical research company’s stock after selling 5,406 shares during the period. New York State Common Retirement Fund’s holdings in IQVIA were worth $20,147,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of IQV. FMR LLC grew its holdings in shares of IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares during the last quarter. JPMorgan Chase & Co. boosted its position in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after buying an additional 583,396 shares during the period. Impax Asset Management Group plc increased its holdings in shares of IQVIA by 9.7% in the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after buying an additional 157,809 shares during the period. Nordea Investment Management AB lifted its stake in shares of IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in IQVIA by 3.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock valued at $290,545,000 after acquiring an additional 39,772 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on IQV shares. Morgan Stanley boosted their price objective on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Barclays lowered their price target on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. Leerink Partners reissued an “outperform” rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $251.22.

Insider Activity at IQVIA

In related news, Director John G. Danhakl bought 1,275 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The shares were purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now owns 1,275 shares in the company, valued at approximately $255,739.50. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.60% of the stock is owned by corporate insiders.

IQVIA Stock Performance

Shares of IQVIA stock opened at $190.94 on Friday. The business has a fifty day simple moving average of $199.57 and a two-hundred day simple moving average of $216.49. The firm has a market capitalization of $33.62 billion, a P/E ratio of 25.46, a P/E/G ratio of 1.99 and a beta of 1.48. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.